2025-02-23T14:58:33-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: Query fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-145224%22&qt=morelikethis&rows=5
2025-02-23T14:58:33-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: => GET http://localhost:8983/solr/biblio/select?fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-145224%22&qt=morelikethis&rows=5
2025-02-23T14:58:33-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: <= 200 OK
2025-02-23T14:58:33-05:00 DEBUG: Deserialized SOLR response
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy

Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy

Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage a...

Full description

Saved in:
Bibliographic Details
Main Authors: Giesel, F.L., Flechsig P., Kuder T., Schwartz L., Wulfert S., Zechmann C., Bruchertseifer F., Haberkorn U., Kratochwil C.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Series:Experimental Oncology
Subjects:
Original contributions
Online Access:http://dspace.nbuv.gov.ua/handle/123456789/145224
Tags: Add Tag
No Tags, Be the first to tag this record!
id irk-123456789-145224
record_format dspace
spelling irk-123456789-1452242019-01-20T01:23:24Z Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy Giesel, F.L. Flechsig P. Kuder T. Schwartz L. Wulfert S. Zechmann C. Bruchertseifer F. Haberkorn U. Kratochwil C. Original contributions Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response criteria. 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective study. Eleven patients were treated with beta-emitting ¹⁷⁷Lu/⁹⁰Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) (n = 6) and three patients received alpha-emitting ²¹³Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed before and 3 months after treatment. CE-CT and CEUS presented comparable results in the baseline study and in the assessment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor of longterm morphologic response. Conclusion: CEUS is available and radiation free technique which showed comparable results for perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a positive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitoring early treatment after focal alpha and beta targeted therapy. Key Words: contrast-enhanced ultrasound, radionuclide therapy, treatment response, DOTATOC PET/CT. 2013 Article Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145224 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Giesel, F.L.
Flechsig P.
Kuder T.
Schwartz L.
Wulfert S.
Zechmann C.
Bruchertseifer F.
Haberkorn U.
Kratochwil C.
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
Experimental Oncology
description Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response criteria. 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective study. Eleven patients were treated with beta-emitting ¹⁷⁷Lu/⁹⁰Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) (n = 6) and three patients received alpha-emitting ²¹³Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed before and 3 months after treatment. CE-CT and CEUS presented comparable results in the baseline study and in the assessment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor of longterm morphologic response. Conclusion: CEUS is available and radiation free technique which showed comparable results for perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a positive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitoring early treatment after focal alpha and beta targeted therapy. Key Words: contrast-enhanced ultrasound, radionuclide therapy, treatment response, DOTATOC PET/CT.
format Article
author Giesel, F.L.
Flechsig P.
Kuder T.
Schwartz L.
Wulfert S.
Zechmann C.
Bruchertseifer F.
Haberkorn U.
Kratochwil C.
author_facet Giesel, F.L.
Flechsig P.
Kuder T.
Schwartz L.
Wulfert S.
Zechmann C.
Bruchertseifer F.
Haberkorn U.
Kratochwil C.
author_sort Giesel, F.L.
title Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
title_short Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
title_full Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
title_fullStr Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
title_full_unstemmed Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy
title_sort contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷lu/⁹⁰y-dotatoc and ²¹³bi-dotatoc radiopeptide therapy
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2013
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/145224
citation_txt Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT gieselfl contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT flechsigp contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT kudert contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT schwartzl contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT wulferts contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT zechmannc contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT bruchertseiferf contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT haberkornu contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
AT kratochwilc contrastenhancedultrasoundmonitoringofperfusionchangesinhepaticneuroendocrinemetastasesaftersystemicversusselectivearterial177lu90ydotatocand213bidotatocradiopeptidetherapy
first_indexed 2023-05-20T17:21:33Z
last_indexed 2023-05-20T17:21:33Z
_version_ 1796153116975955968

Similar Items